CST, 48143S, Human VEGF-165 Recombinant Protein

Storage
Human VEGF-165 Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/ml which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.
Source / Purification
Recombinant human VEGF-165 was expressed in and is supplied in a lyophilized form.
Background
VEGF-165 is the most abundant splice variant of VEGF-A (1,2). VEGF-165 is produced by a number of cells including endothelial cells, macrophages, and T cells. VEGF-165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration, and vascular permeability (1). gene expression is induced by hypoxia, inflammatory cytokines, and oncogenes (1,2). VEGF-165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF-165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF-165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF-165 to VEGFR1 and VEGFR2 leads to activation of PI3K/Akt, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).